Genmab A/S (GMAB )

Currency in USD Disclaimer
$57.06 +$0.57 (1.01%)
Closed 10/30/2026
$56.53
$59.02
$23.62
$35.66

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol GMAB
  • Company Genmab A/S
  • Price $57.06
  • Changes Percentage 1.01
  • Change 0.57
  • Day Low $56.53
  • Day High $59.02
  • Year High $35.66
  • Year Low $23.62
  • Market Cap $21,383,387,049
  • Price Avg 50 EMA (D) $31.77
  • Price Avg 200 EMA (D) $29.5
  • Exchange NASDAQ
  • Volume 2,514,918
  • Average Volume 2,270,714
  • Open $57.3
  • Previous Close $56.49
  • EPS 1.33
  • PE 26.25
  • Earnings Announcement 2026-11-05 05:00:00
  • Shares Outstanding $613,935,890

Company brief: GENMAB A/S (GMAB )

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Corporation News

Genmab Stock Hits 52-Week High - Here's Why

Genmab Stock Hits 52-Week High - Here's Why

October 28, 2026 at 5:44 pm ET

benzinga.com -- Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigation...

Income Statement